TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
SLS

Sellas Life Sciences Group Inc

Healthcare · Biotechnology · —

11.30$ -2.5% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

Sellas Life Sciences Group Inc (SLS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 145 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SLS
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
73 66 70 61 50 34 33 32 38 17 15 25 21 17 17 15 19 46 41 44 38 26 21 32 26 21 29 19 8.1 6.2 24 15 27 19 35 32 52 78 114 145
44 37 42 32 27 13 13 11 18 5.8 3.4 14 10 8.2 8.8 5.2 9.3 37 31 35 29 23 18 29 23 18 26 16 5.2 3.2 22 12 24 16 32 29 49 75 111 143
25 18 28 18 13 2.3 3.5 1.3 10.0 5.3 2.6 13 9.1 7.3 6.7 3.3 8.2 35 28 30 26 21 14 27 21 17 24 14 4.0 2.5 18 9.1 21 14 28 25 44 72 107 138
25 18 28 18 13 13 3.5 1.3 10.0 5.3 2.6 13 9.1 7.3 6.7 3.3 8.2 35 28 30 26 21 14 27 21 17 24 14 4.0 2.5 18 9.1 21 14 28 25 44 72 107 138
– – – – – – – – 6.6 – – – – 0.3 0.3 – – 1.1 0.3 2.2 – – 1.0 – – – – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 – – – – 0.6 – – – 0.5 3.1 2.4 – – 2.6 – – – – – – – – – – – – – – – – –
0.2 0.2 0.2 0.1 0.1 0.0 0.0 0.0 0.0 – 0.5 0.4 0.3 0.2 0.1 1.0 0.9 0.9 0.9 0.8 0.8 0.7 1.1 1.0 1.0 0.9 – 0.7 – – – – – – – – – – – –
5.9 5.9 5.9 5.9 5.4 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9
22 22 22 22 17 18 18 18 18 8.5 8.5 8.5 8.5 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 – – – – – – – – – – – – – – – – – – –
49 37 43 41 35 31 35 34 20 12 12 11 11 11 9.0 11 11 18 12 10 11 6.1 17 13 13 16 16 14 12 14 15 12 11 10.0 7.2 6.2 5.9 7.5 6.8 7.7
43 30 36 35 28 25 26 25 12 6.0 5.8 5.4 5.6 5.3 3.6 4.3 4.2 12 6.0 4.2 5.3 5.0 11 12 13 16 16 13 12 14 14 12 11 9.5 6.9 6.0 5.9 7.0 6.5 7.6
24 16 13 13 12 8.4 8.5 7.8 0.1 – 0.4 0.4 0.3 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.4 0.4 0.4 0.4 0.5 0.4 0.5 0.5 0.6 0.5 0.6 0.6 0.6 0.5 0.6 0.6
0.9 0.8 1.2 0.4 0.2 15 11 12 7.2 3.8 4.6 3.8 3.8 3.9 2.6 2.4 1.8 4.7 2.4 2.3 2.5 2.1 2.8 3.3 2.1 3.4 3.1 3.7 4.3 5.6 7.4 6.3 4.5 3.5 3.8 3.3 2.3 2.9 3.6 3.1
0.0 5.7 0.0 0.0 0.0 2.6 1.2 0.0 0.0 – 0.1 – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
24 29 27 19 15 2.1 -1.3 -2.5 18 5.2 3.0 14 11 6.1 8.1 3.8 7.9 28 29 33 27 20 4.0 19 13 4.9 13 4.8 -3.8 -8.0 9.7 2.9 16 9.5 28 26 46 71 107 138
-297 -303 -315 -323 -329 -54 -62 -68 -69 -82 -86 -90 -94 -101 -105 -110 -114 -118 -120 -125 -132 -139 -155 -164 -171 -180 -191 -200 -209 -217 -227 -234 -241 -248 -254 -261 -267 -275 -283 -293
0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.4 0.4 0.4 0.6 4.3 4.8 6.4 6.7 8.4 10 15 15 16 16 16 20 21 21 24 28 28 31 45 58 68 74 88 99 108 153 172 189

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?